Central GPR55 may prevent nicotine reinforcing actions: a preliminary study

Alejandro Díaz-Barba, Argelia Calvillo-Robledo, Priscila Vázquez-León, Eduardo Gallegos-Vieyra, J Luis Quintanar, Bruno A Marichal-Cancino. Acta Neurobiol Exp (Wars). 2022;82(3):304-314.

Laboratory studyOther animals

Design

Laboratory study

Subjects

Rodents in a conditioned place preference paradigm; species and numbers not stated in the abstract

Dose used in the study

Injections of LPI, palmitoylethanolamide, ML184 or ML193; doses and route not stated in the abstract

Duration

Not stated in the abstract

What was measured

Nicotine-induced conditioned place preference after injection of GPR55 agonists or antagonist.

What the authors reported

Injections of LPI, PEA, the GPR55 agonist ML184 and the GPR55 antagonist ML193 each interfered with nicotine-induced place preference. The authors state the mechanisms remain to be identified and probably include central GPR55.

Limits of this study

A preliminary animal study described by the authors as a pilot; it cannot show effect in people. Species, numbers and doses are not in the abstract. Funding and conflicts not stated in the abstract.

Source

PubMed 36214713 · doi:10.55782/ane-2022-029

Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.